Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in stage IV or recurrent NSCLC
2009-017396-19Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ipilimumab + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival in subjects with stage IV/recurrent NSCLC of squamous histology. Started Feb 2011; status: completed.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-017396-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017396-19.